An interventional study of Unscheduled AI Flyer and Scheduled AI Flyer in Hypertension, sponsored by Wake Forest University Health Sciences. Active, not recruiting at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Wake Forest University Health Sciences · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Hypertension by Wake Forest University Health Sciences — 4 open to participants now, 7 under way, none of them phase 3. Hypertension · Wake Forest University Health Sciences.
Among the 25 studies in Hypertension by Wake Forest University Health Sciences, this one is the 4th largest by enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2026, is one of 17 with no phase, and was the 25th registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →4 of the 25 studies in Hypertension by Wake Forest University Health Sciences are open now, in 1 country. Recruiting first, the newest first:
Wake Forest University Health Sciences · Sites in United States
Ages 18–45 · Women only
Wake Forest University Health Sciences · Sites in United States
Ages 18+
Wake Forest University Health Sciences · Sites in United States
Ages 7–18 · Healthy volunteers
Wake Forest University Health Sciences · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 155 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 41 across the 20 interventional studies, 125 across the 5 observational. Of the 16 that completed or were terminated, 7 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
Wake Forest University Health Sciences is the lead sponsor of 1,353 studies on the registry; 199 are open to participants now.
Of its 332 completed or terminated interventional studies of FDA-regulated products, 251 (76%) have results posted.
4 of the studies in Hypertension by Wake Forest University Health Sciences that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07356518Wake Forest University Health SciencesTelehealth and Remote Blood Pressure | 2026-12 |
| NCT04752293Wake Forest University Health SciencesPediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE) | 2026-12 |
| NCT07693699Wake Forest University Health SciencesOptimizing Sustainable Cuff Access and Training Pathways for Self-Measured Blood Pressure Monitoring in Primary Care | 2026-12-01 |
| NCT06527794Wake Forest University Health SciencesRemote Hypertension Management for Black Patients | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 25 studies in Hypertension by Wake Forest University Health Sciences, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to evaluate AI Virtual Assistant-supported blood pressure reading return pathways that support delivery of a SMBP program in routine primary care, among adult primary care patients with uncontrolled hypertension
The criteria were revised on the registry on Nov 18, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Patients will be provided an educational infographic and AI Virtual Assistant flyer. No specific AI outreach date or time is scheduled with the patient.
Behavioral: Unscheduled AI Flyer
Patients will be provided an educational infographic and an AI Virtual Assistant flyer. The MA or RA will work with the patient to identify a preferred date and time for AI outreach and document the scheduled outreach time on the flyer.
Behavioral: Scheduled AI Flyer
Provide patient with an AI flyer
The MA or RA will work with the patient to identify a preferred date and time for AI outreach and document the scheduled outreach time on the flyer.
SMBP Reading Return
Proportion of randomized patients with a home blood pressure reading obtained through AI Virtual Assistant outreach and documented in the EHR.
Time frame: 14 Days
AI Virtual Assistant Engagement
Proportion of randomized patients who complete the AI Virtual Assistant call.
Time frame: 14 Days
SMBP Reading Return Among Engaged Patients
Among patients who complete the AI Virtual Assistant call, proportion who provide a home blood pressure reading.
Time frame: 14 Days
SMBP Reading Documentation at 3 Months
Proportion of patients with any SMBP reading documented in Epic.
Time frame: 3 Months
Home BP Cuff Access
Proportion of patients reporting access to a home blood pressure cuff.
Time frame: 21 Days
Distribution of Cuff Access Pathways
Distribution of patients who: already own a cuff, accept insurance-supported acquisition assistance, plan independent purchase, or do not wish to obtain a cuff.
Time frame: Enrollment
Workflow Implementation
Completion of key workflow activities, including cuff-access assessment, randomization assignment, flyer distribution, and AI outreach completion.
Time frame: 3 Months
Change in Systolic Blood Pressure
Change in systolic blood pressure using routinely documented clinic measurements.
Time frame: 3 Months
Medication Intensification
Addition of an antihypertensive medication, dose increase, or regimen intensification.
Time frame: 3 Months
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Dec 2026, 4 months after the start.
Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 4 months is below that.
Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Oct 2026 → Dec 2026 and completion Nov 2026 → Feb 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wake Forest University Health Sciences →